Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellectis (CLLS) EBIT Margin: 2015-2023

Historic EBIT Margin for Cellectis (CLLS) over the last 9 years, with Sep 2023 value amounting to -13,336.13%.

  • Cellectis' EBIT Margin rose 229416.00% to -13,336.13% in Q3 2023 from the same period last year, while for Sep 2023 it was -444.85%, marking a year-over-year increase of 36396.00%. This contributed to the annual value of -348.56% for FY2022, which is 8045.00% down from last year.
  • Cellectis' EBIT Margin amounted to -13,336.13% in Q3 2023, which was down 0.50% from -13,270.22% recorded in Q2 2023.
  • Cellectis' 5-year EBIT Margin high stood at 28.75% for Q1 2020, and its period low was -16,856.83% during Q1 2023.
  • In the last 3 years, Cellectis' EBIT Margin had a median value of -1,755.44% in 2022 and averaged -5,830.56%.
  • Its EBIT Margin has fluctuated over the past 5 years, first soared by 287,627bps in 2019, then tumbled by 1,512,056bps in 2022.
  • Over the past 5 years, Cellectis' EBIT Margin (Quarterly) stood at -870.34% in 2019, then surged by 58,340bps to -286.94% in 2020, then skyrocketed by 4,761bps to -239.33% in 2021, then surged by 20,401bps to -35.32% in 2022, then surged by 229,416bps to -13,336.13% in 2023.
  • Its EBIT Margin stands at -13,336.13% for Q3 2023, versus -13,270.22% for Q2 2023 and -16,856.83% for Q1 2023.